ELKTON, Va. (WHSV) - Pharmaceutical giant, Merck & Co., is investing $3 billion dollars to construct a new manufacturing facility on its Elkton campus to help cement Virginia as a Life Sciences Hub for Innovation. Ground broke for the new 400,000 …

Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary …

MSD, known as Merck & Co. in the U.S. and Canada, won Korean approval for Capvaxive, a vaccine that protects against 21 different strains of the bacteria that cause pneumococcal disease in adults. To discuss this milestone and Capvaxive’s upcoming …

When a German manufacturer of blow-fill-seal (BFS) equipment for sterile pharmaceutical products looked to expand into the United States three decades ago, it initially considered a California site, until the Golden State’s high manufacturing costs had the …

RICHMOND, VA — Merck & Co. is beginning construction on a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility in Elkton, Virginia. Virginia Governor Glenn Youngkin yesterday announced that the company, known as MSD outside of the U.S. …

There were also decent performances from General Motors and GE Aerospace as results impressed, while Warner Bros Discovery jumped on M&A speculation. “This earnings season was always going to be a doozy, with investors keenly waiting to see how tariffs …

The pharmaceutical sector in Virginia continues its momentum with Merck & Co. beginning construction on a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility in the city of Elkton. Merck & Co., known as MSD outside of the United …

The basics: Merck will invest $3B in a new 400,000-sf facility in Virginia Site will serve as Merck’s Center of Excellence for Pharmaceutical Ingredients Project will create 500 jobs and strengthen nation’s life sciences sector Construction to begin in …

Overall, around 50% of all recurrent ovarian cancers are platinum-resistant. The market is expected to grow from about US$3.3bn in 2022 to US$5.6bn by 2030. Tubulis’ ADC TUB-040, targeting the NaPi2b cancer antigen, showed typical ADC activity in 66 …

Astute Analytica’s latest report reveals that the clinical pipeline for hospital infection therapeutics exposes key innovation gaps and emerging opportunities for investment across antibiotic and antifungal segments. Chicago, Oct. 21, 2025 (GLOBE NEWSWIRE) …